Analyst Upgrades

• Deere (DE) to outperform from market perform at Wells Fargo.
• American Eagle (AEO) to buy from neutral at Janney Capital.
• FedEx (FDX) and Shaw (SJR) to outperform from neutral at Credit Suisse.
• Superior Energy (SPN) and Rowan Cos. (RDC) to overweight from equal weight at Barclays.
• Tesoro (TSO) to outperform from neutral at Macquarie.
• Mechel (MTL) to buy from neutral at Goldman.
• SunPower (SPWRA), LDK Solar (LDK) and First Solar (FSLR) to buy from hold at ThinkEquity.

Drugmaker Schering-Plough Corp. (NYSE: SGP) reported this morning a drop of 48% in its fiscal first-quarter profit, hurt by higher costs tied to a buyout in the prior quarter. However, the company was able to post adjusted earnings well above analysts' predictions, pushing its shares up in morning trading.

Schering-Plough's profit during the first-quarter plunged to $291 million, or 15 cents a share, dragged down by charges related to its acquisition of Organon Biosciences NV. Excluding items, Schering-Plough's earnings figures would have come at 53 cents per share. Analysts' forecasts (which typically exclude one time items) were for 37 cents per share in the quarter.

The company's quarterly revenue jumped by a respectable 57% to $4.66 billion. For the period, the company benefited from strong gains from Organon, which came with sales of $1.3 billion. Anti-inflammatory Remicade sales also saw a growth of 36%, while allergy treatment Nasonex revenue saw a rise of 8%. Higher drug prices offset lower prescriptions in the U.S. Analysts, on average, expected Schering-Plough's revenue to be $4.52 billion, according to Thomson Reuters.